Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.
Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.
